King’s College London, one of the top 25 universities in the world, is teaming up with Parkinson’s UK for a £1.2-million clinical trial to determine the safety and efficacy of CBD in treating Parkinson’s-related psychosis, characterized by hallucinations and delusions.
The clinical trial will determine, for the first time, whether CBD can correct the abnormal functioning of the brain that is causing symptoms such as hallucinations and delusions.
For the first time, a clinical study has identified how CBD alters brain function in ways that may correlate with improvements in … More
Large clinical trial – King’s College London – seeks to affirm CBD as a treatment for psychosis..
“CBD has emerged as a promising candidate as it displays anti-anxiety and anti-psychotic like properties in animals and humans.”
New clinical study today announced by Phoenix-based biomed company will explore CBD oral solution on symptoms of early psychosis plus the drive behind excessive eating behaviour that accompanies antipsychotic medication use.
Scientific evidence of cannabinoids as safe, effective treatment for schizophrenia is so powerful, compelling and widespread that it’s almost indisputable.
Why did it take us so long to get here?
CBD has beneficial effects in patients with schizophrenia and may represent a new class of treatment for the disorder.